Alphamab Oncology (9966.HK)

Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (BsAb) that is in Phase III clinical trials to treat HER2-positive breast cancer and HER2-positive gastric cancer or gastroesophageal junction cancer; KN046, a BsAb immune checkpoint inhibitor in Phase III clinical trial for the treatment of non-small cell lung cancer (NSCLC), squamous NSCLC, triple-negative breast cancer, and recurrent and metastatic esophageal squamous cell carcinoma; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC) that is in Phase III clinical trial to treat HER2-expressing advanced or metastatic solid tumors, HER2-low expression breast cancer, platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. In addition, the company is developing JSKN016, a bispecific ADC that is in Phase II clinical trial for the treatment of solid tumors, lung cancer, and breast cancer; JSKN022, a bispecific single-domain antibody; JSKN027, a bispecific ADC that is Phase I clinical trial; JSKN021; KN019; and JSKN033, a subcutaneous ADC in Phase I clinical trial to treat HER2-expressing advanced or metastatic solid tumors. The company also develops JSKN029, a pre-clinical stage product for oncology applications. Alphamab Oncology was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.